Biomarker testing for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study).
Junichi ShimizuKatsuhiro MasagoHaruhiro SaitoKazumi NishinoTakayasu KurataYohji ItohYoko YoshimuraYutaka YabukiHirotoshi Dosaka-AkitaPublished in: Therapeutic advances in medical oncology (2020)
The proportion of nonsquamous NSCLC patients with confirmed biomarker status for first-line treatment was considered insufficient and in need of improvement.